Novavax has submitted a type II variation application to the EMA for its NVX-CoV2705 COVID-19 vaccine, targeting authorization for people aged 12 and over in Europe.

The vaccine is designed to target the JN.1 lineage, with confirmed efficacy against currently circulating variants, including KP.2 and KP.3.

Preclinical data show that it induces polyfunctional and targeted immune responses, reinforcing its potential to respond to mutations and variants.

Novavax is also preparing submissions to the FDA and other global regulatory authorities, aiming to distribute its vaccine in single-dose vials upon approval.


Copyright (c) 2024 CercleFinance.com. All rights reserved.